Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism
US8778894B2 · kind B2 · utility
3Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 4, 2013 |
| Grant date | Jul 15, 2014 |
| Priority date | — |
| Expiry date | Oct 4, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.